GLP-1 Supply Tracker: What the FDA Lists Today
Three of the four GLP-1 ingredients tracked here had no current shortage record at the FDA on November 19, 2026: semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®) and dulaglutide (Trulicity®). The fourth, liraglutide (Saxenda®, Victoza®), is listed with limited availability.1 The table below requests the FDA’s newest list every time this page opens.
Status for each brand and strength
Saved copySaved by AM Rx on November 19, 2026 at 12:14 PM EST. A status may have changed since this copy was made.
The FDA lists a shortage for 2 of the 7 brands below: Saxenda and Victoza.
- Ozempic None listed
- Wegovy None listed
- Mounjaro None listed
- Zepbound None listed
- Saxenda Shortage listed
- Victoza Shortage listed
- Trulicity None listed
- No shortage listed
- Shortage listed by FDA
- Being discontinued
| Strength | What the FDA lists |
|---|---|
Ozempic semaglutide No shortage listed | |
| 0.68 mg/1 mL Pen that gives 0.25 mg or 0.5 mg | No shortage listed |
| 1.34 mg/1 mL Pen that gives 1 mg | No shortage listed |
| 2.68 mg/1 mL Pen that gives 2 mg | No shortage listed |
| 1.5 mg Tablet | No shortage listed |
| 4 mg Tablet | No shortage listed |
| 9 mg Tablet | No shortage listed |
Wegovy semaglutide No shortage listed | |
| 0.25 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 0.5 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 1 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 1.7 mg/0.75 mL Prefilled pen (single dose) | No shortage listed |
| 2.4 mg/0.75 mL Prefilled pen (single dose) | No shortage listed |
| 7.2 mg/0.75 mL Prefilled pen (single dose) | No shortage listed |
| 1.5 mg Tablet | No shortage listed |
| 4 mg Tablet | No shortage listed |
| 9 mg Tablet | No shortage listed |
| 25 mg Tablet | No shortage listed |
Mounjaro tirzepatide No shortage listed | |
| 2.5 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 5 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 7.5 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 10 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 12.5 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 15 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
Zepbound tirzepatide No shortage listed | |
| 2.5 mg/0.5 mL Prefilled pen or vial (single dose) | No shortage listed |
| 5 mg/0.5 mL Prefilled pen or vial (single dose) | No shortage listed |
| 7.5 mg/0.5 mL Prefilled pen or vial (single dose) | No shortage listed |
| 10 mg/0.5 mL Prefilled pen or vial (single dose) | No shortage listed |
| 12.5 mg/0.5 mL Prefilled pen or vial (single dose) | No shortage listed |
| 15 mg/0.5 mL Prefilled pen or vial (single dose) | No shortage listed |
| 10 mg/2.4 mL KwikPen (4 doses of 2.5 mg) | No shortage listed |
| 20 mg/2.4 mL KwikPen (4 doses of 5 mg) | No shortage listed |
| 30 mg/2.4 mL KwikPen (4 doses of 7.5 mg) | No shortage listed |
| 40 mg/2.4 mL KwikPen (4 doses of 10 mg) | No shortage listed |
| 50 mg/2.4 mL KwikPen (4 doses of 12.5 mg) | No shortage listed |
| 60 mg/2.4 mL KwikPen (4 doses of 15 mg) | No shortage listed |
Saxenda liraglutide Shortage listed by FDA | |
| 6 mg/1 mL Prefilled pen (multiple doses) | Shortage listed by FDA
|
| Being discontinued. The FDA holds a discontinuation notice for Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15), dated 08/25/2026. FDA note: Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug. | |
Victoza liraglutide Shortage listed by FDA | |
| 6 mg/1 mL Prefilled pen (multiple doses) | Shortage listed by FDA
|
Trulicity dulaglutide No shortage listed | |
| 0.75 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 1.5 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 3 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
| 4.5 mg/0.5 mL Prefilled pen (single dose) | No shortage listed |
Strengths and package types are taken from the current labels of Ozempic injection2 and tablets,3 Wegovy,4 Mounjaro,5 Zepbound,6 Saxenda,7 Victoza8 and Trulicity.9 Any other package gets its own row if the FDA posts a current record for it.
10 more FDA records: generics and other brands
| Package and company | What the FDA lists |
|---|---|
| Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) Novo Nordisk, Inc. | Being discontinued
|
| Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) Novo Nordisk, Inc. | Being discontinued
|
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) Meitheal Pharmaceuticals, Inc. | Shortage listed by FDA
|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) Novo Nordisk, Inc. | Shortage listed by FDA
|
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) Meitheal Pharmaceuticals, Inc. | Shortage listed by FDA
|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) Novo Nordisk, Inc. | Shortage listed by FDA
|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) Hikma Pharmaceuticals USA, Inc. | Shortage listed by FDA
|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) Teva Pharmaceuticals USA, Inc. | Being discontinued
|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) Hikma Pharmaceuticals USA, Inc. | Shortage listed by FDA
|
| Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) Novo Nordisk, Inc. | Being discontinued
|
See it on the FDA’s own site
- Semaglutide: Semaglutide Tablet (discontinuation page)
- Tirzepatide: nothing in this data. Look it up in the FDA database (tirzepatide)
- Liraglutide: Liraglutide Injection (current shortage page), Liraglutide Injection (discontinuation page)
- Dulaglutide: nothing in this data. Look it up in the FDA database (dulaglutide)
Data provided by the U.S. Food and Drug Administration (https://open.fda.gov). The FDA asks that openFDA data not be used to make medical care decisions.10 This table repeats FDA records. It does not show any pharmacy’s stock.
Is your strength hard to fill?
A licensed AM Rx provider can review your history and go over other options with you.
Get StartedSeeing a gap the FDA has not listed?
The FDA takes reports of new shortages from the public, then checks supply with the manufacturers.
Report it on the FDA’s siteWhere does this GLP-1 shortage tracker get its data?
Each time this page opens, your browser sends one request to openFDA, a public data service run by the FDA, for every shortage record filed under semaglutide, tirzepatide, liraglutide or dulaglutide. The FDA refreshes that data daily.10 On November 19, 2026 the answer held 14 records.1
Each record describes one package, such as “Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)”. The page files it under the brand and strength it names:
- Shortage listed by FDA. A record with the FDA status “Current” fits that strength. The row repeats the maker’s report, the reason, any FDA note and the record date.
- No shortage listed. No current record fits.
- Being discontinued. The FDA holds a “To Be Discontinued” record for the brand.
Generic liraglutide, Rybelsus® and any other product outside these seven brands go in the panel under the table.
Live data or a saved copy
The box above the table says which one you are seeing. If the FDA cannot be reached, the page shows the copy AM Rx saved on November 19, 2026 at 12:14 PM Eastern and labels it “Saved copy” with that date and time. The FDA offers openFDA “as is”, with no promise of uninterrupted access, so a fallback is needed.11
What does an FDA shortage status mean for you?
A shortage status tells you what manufacturers have reported to the FDA about supply for the whole country. It does not tell you what your pharmacy has in stock. Manufacturers provide most of the information,12 and the FDA counts a drug as in shortage when demand or projected demand across the United States exceeds supply.13
What a listing tells you
- The FDA knows. A shortage listed as current means the agency is aware of the supply situation and is working with the manufacturers.12
- What the maker reports. Wording such as “Limited Availability” or “Available” comes from the manufacturer and can change daily.13
What it does not tell you
- Listed does not mean unobtainable. “Available” inside a current record is the manufacturer’s latest report, not an FDA decision that the shortage is over.13 Six generic liraglutide packages are listed that way today.1
- Not listed does not mean every pharmacy has it. The FDA says an out-of-stock drug is usually a temporary, local issue.12 When it declared the semaglutide shortage over, it added that patients “may still see intermittent and limited localized supply disruptions” as product moves from the manufacturer to local pharmacies.14
FDA status today for semaglutide, tirzepatide, liraglutide and dulaglutide
| Ingredient | FDA records on November 19, 2026 | Background |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | None for Ozempic or Wegovy. The 3 records returned are Rybelsus tablets (3 mg, 7 mg, 14 mg), “To Be Discontinued”, dated 06/04/2026.1 | Injection shortage declared resolved on February 21, 2025.14 |
| Tirzepatide (Mounjaro, Zepbound) | None. openFDA answers “No matches found”.1 | Declared resolved on October 2, 2024 and again on December 19, 2024.14 |
| Liraglutide (Saxenda, Victoza) | 11 records. 9 are “Current”: Saxenda and two Victoza packages at “Limited Availability”, six generic packages “Available”. 2 are “To Be Discontinued”: Saxenda (08/25/2026) and one generic (05/14/2026).1 | Current records first posted 07/18/2023. FDA note on Victoza: “Estimated shortage duration: TBD”.1 |
| Dulaglutide (Trulicity) | None.1 | Still described as in shortage on February 21, 2025, with all presentations available.14 |
The FDA’s own Drug Shortages Database showed the same on November 19, 2026: liraglutide injection under “Currently in Shortage”, and no current entry for semaglutide injection, tirzepatide or dulaglutide.15
Saxenda is leaving the market. Novo Nordisk is discontinuing Saxenda in the US, with its last shipments to wholesalers in late January 2027. It says the decision is “not the result of any safety or quality-related concerns”.16
Your GLP-1 dose is out of stock: what to do next
Find out first whether the gap is national or local. Look up your brand and strength in the table, then:
- No shortage listed. The problem is probably local. The FDA’s advice is to check more than one store or pharmacy.13
- Shortage listed. The FDA suggests asking your health care provider or pharmacist about other treatment options during the shortage.12 Do it before your last dose.
- Do not improvise. Do not split doses, stretch the time between them or change strength unless your prescriber says so.
- Recheck coverage before a switch. Coverage can differ from one medication to the next. Our GLP-1 insurance checker is a place to start.
- Tell the FDA. If the drug is not in the FDA’s database, report it through the agency’s public portal.12
AM Rx providers prescribe brand-name GLP-1 medications, including Zepbound, Wegovy, Ozempic and Mounjaro, and only after a licensed provider decides one is right for you. The FDA approved Ozempic and Mounjaro to treat type 2 diabetes. Neither has a weight loss indication.2,5 A brand-name prescription goes to the pharmacy you choose, and our insurance coordination team submits prior authorization requests. The membership fee is $39 for month one, then $135 monthly, with medication billed separately. For drugs still in trials, see the GLP-1 pipeline tracker.
How does shortage status affect compounded semaglutide and tirzepatide?
Shortage status is one of the tests federal law applies to compounded copies of an approved drug, and neither semaglutide injection nor tirzepatide injection is on the FDA’s shortage list today.1 Both were listed from 2022 until the FDA declared the shortages resolved, tirzepatide in late 2024 and semaglutide in February 2025. The agency’s April 1, 2026 update sets out where that leaves compounders:14
- Outsourcing facilities (section 503B) may compound from a bulk drug substance only if it is on the FDA’s 503B bulks list or the drug is on the shortage list. The FDA states that tirzepatide and semaglutide “do not currently appear on the 503B bulks list or on FDA’s drug shortage list”.
- State-licensed pharmacies (section 503A) compound for one patient on a prescription. They may not compound “regularly or in inordinate amounts” a product that essentially copies a drug already on the market. The exception is a change that the prescriber has documented as making a significant difference for that particular patient.
No compounded medication is FDA-approved, and none is reviewed by the FDA for safety, effectiveness or quality before it is sold. The agency says they belong only where no FDA-approved drug can meet the patient’s medical need.17
An AM Rx provider prescribes compounded semaglutide or compounded tirzepatide only after judging it appropriate for that patient. It ships from a partner pharmacy.
Important safety information for GLP-1 medications
Boxed warning: risk of thyroid C-cell tumors. Every brand in the table carries this warning.2,4,5,6,7,8,9 These medications are not for anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and anyone who has reacted severely to the drug before.
Other serious risks are inflammation of the pancreas, gallbladder problems, low blood sugar when taken with insulin or a sulfonylurea, kidney injury from dehydration, severe stomach problems and serious allergic reactions. Nausea, diarrhea, vomiting, constipation and stomach pain are the side effects reported most often.4,6
This is a summary. Read the full safety information for Wegovy, Ozempic, Zepbound, Mounjaro, compounded semaglutide and compounded tirzepatide.
Questions about GLP-1 supply
Is Ozempic still in shortage?
No. The FDA held no shortage record for any semaglutide injection on November 19, 2026, and that covers Ozempic and Wegovy pens. It declared the shortage resolved on February 21, 2025.1,14 Ozempic is approved for adults with type 2 diabetes and has no weight loss indication.2
Is Zepbound or Mounjaro still on the FDA shortage list?
No. As of November 19, 2026 the FDA has no shortage or discontinuation record for tirzepatide, the ingredient in both. The agency declared the shortage over on October 2, 2024, re-examined that decision and reached the same answer on December 19, 2024.1,14 The table above repeats the check on every visit.
Why is Saxenda so hard to find?
Saxenda is on the FDA list with limited availability because it is being discontinued.1 Novo Nordisk says its last shipments to US wholesalers will be in late January 2027, and that the decision is not about safety or quality.16 Ask your prescriber about a replacement well before your supply ends.
Is Rybelsus being discontinued?
The FDA lists the 3, 7 and 14 mg strengths of Rybelsus as to be discontinued, in records dated June 4, 2026, with a note that Ozempic (semaglutide) tablets will replace them.1 No end date is given. The label says the two are not interchangeable milligram for milligram, so a prescriber sets the new strength.3
How often does this tracker update?
Every time you open the page. Your browser requests the current records from openFDA, and the FDA refreshes them daily.10 The box above the table shows when your copy loaded. The Refresh button asks again, with a 10 second pause between requests.
What does the page show if the FDA’s data service is down?
A saved copy, clearly labeled. AM Rx took it from the FDA on November 19, 2026 at 12:14 PM Eastern, and the box above the table reads “Saved copy” with that date and time until a live request succeeds. A status can change after a copy is made, so confirm it on the FDA’s site.
The tracker shows no shortage. Why can’t my pharmacy fill my prescription?
Because the FDA measures supply for the whole country, not for one store. It says an empty shelf is usually a temporary, local issue and suggests checking several pharmacies.12,13 Ask yours when the next delivery is due, and tell your prescriber if you may miss a dose.
Does “limited availability” mean I cannot fill my prescription?
Not necessarily. “Limited Availability” is the manufacturer’s wording in its report to the FDA, which tracks shortages nationally, not pharmacy by pharmacy.13 Some pharmacies will have the product and some will not. Call ahead, and ask your prescriber about a backup before you run out.
Can pharmacies still compound semaglutide or tirzepatide now that the shortages are over?
Only within FDA limits. A state-licensed pharmacy may compound for an individual prescription, but may not routinely copy a drug that is already on the market, unless the prescriber has documented a difference that matters for that patient. The FDA says it does not intend to act when a compounder fills four or fewer such prescriptions in a calendar month.14 No compounded medication is FDA-approved.17
Who do I tell if I cannot get my GLP-1 anywhere?
Tell the FDA, through the public portal for new shortages that is linked from its drug shortages page. Search the Drug Shortages Database for the generic name first, and report only if the drug is not there. Updates on a shortage already listed go by email to drugshortages@fda.hhs.gov.12
Sources
- U.S. Food and Drug Administration. openFDA drug shortages endpoint. Queried November 19, 2026 at 12:14 PM Eastern for semaglutide, tirzepatide, liraglutide and dulaglutide. https://api.fda.gov/drug/shortages.json
- Ozempic (semaglutide) injection. Prescribing Information. Novo Nordisk. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- Ozempic and Rybelsus (oral semaglutide) tablets. Prescribing Information. Novo Nordisk. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- Wegovy (semaglutide) injection and tablets. Prescribing Information. Novo Nordisk. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Mounjaro (tirzepatide). Prescribing Information. Eli Lilly and Company. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- Zepbound (tirzepatide). Prescribing Information. Eli Lilly and Company. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Saxenda (liraglutide). Prescribing Information. Novo Nordisk. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- Victoza (liraglutide). Prescribing Information. Novo Nordisk. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
- Trulicity (dulaglutide). Prescribing Information. Eli Lilly and Company. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
- U.S. Food and Drug Administration. openFDA: Drug Shortages overview. https://open.fda.gov/apis/drug/drugshortages/
- U.S. Food and Drug Administration. openFDA Terms of Service. https://open.fda.gov/terms/
- U.S. Food and Drug Administration. Drug Shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
- U.S. Food and Drug Administration. Frequently Asked Questions about Drug Shortages. https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Updated April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Drug Shortages Database: current and resolved drug shortages and discontinuations reported to FDA. Viewed November 19, 2026. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- Novo Nordisk. Saxenda discontinuation notice. https://www.saxenda.com/
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Ask a licensed provider about a GLP-1 you can fill
The health questionnaire takes a few minutes and is read by a licensed provider. Your first month of AM Rx membership is $39.

A status describes supply. A provider helps you decide what to do next.
A U.S.-licensed AM Rx provider reviews each new intake online, usually within 1 to 2 business days. If your medication or strength is hard to fill, you can message your care team about the options.
The AM Rx care team checks the medical content of this page against FDA prescribing information and published clinical trials. It is general health education and does not replace advice from your own provider.
AM Rx members, in their own words
One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
I started semaglutide at the recommendation of my AM Rx provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and AM Rx was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Since I started AM Rx, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Individual results may vary. These reviews describe the experience of individual AM Rx members and do not promise any result. Medication is prescribed only if a licensed provider considers it appropriate.
The GLP-1 medications AM Rx providers prescribe
Four brand-name medications and two compounded options. Which one you are offered depends on your health history and a licensed provider’s judgment, and our insurance coordinators file the prior authorization when a brand-name drug is prescribed.
Zepbound®
Weekly tirzepatide. FDA-approved for chronic weight management and for obstructive sleep apnea in adults with obesity.
Zepbound cost, coupons and side effects →Wegovy®
Semaglutide for chronic weight management, FDA-approved as a weekly injection and as a once-daily tablet.
Wegovy pill, price and side effects →Mounjaro®
Weekly tirzepatide with an FDA approval for type 2 diabetes. It shares its active ingredient with Zepbound.
Mounjaro doses and savings card →Ozempic®
Weekly semaglutide with an FDA approval for type 2 diabetes. Using it for weight loss is off-label.
Ozempic side effects and cost →Compounded semaglutide
$199 a month, or from $106 a month when you order a 3-month supply. Shipping is included. Not FDA-approved.
Semaglutide cost and dosing →Compounded tirzepatide
$329 a month, or from $216 a month when you order a 3-month supply. Shipping is included. Not FDA-approved.
Tirzepatide dosage and cost →A partner pharmacy prepares compounded medication for one patient’s prescription at a time. Compounded drugs are not FDA-approved: the FDA does not review them for safety, effectiveness or quality. AM Rx membership costs $39 for the first month and $135 a month after that, and is charged separately from medication. Nothing is prescribed unless a licensed provider finds it appropriate.